Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Designer Labeling: Drug Safety Reform Proposals Include New Powers for FDA

This article was originally published in RPM Report

Executive Summary

The time has come when the pharmaceutical industry will have to answer for Vioxx. Congress will address drug safety in 2007. That means FDA could get new authority over the heart and soul of any new drug-the label.
Advertisement

Related Content

The Era of Drug Efficacy
FDA Leadership Changes Reflect Budgetary, Scientific Challenges
The Power of the Purse: FDA Seeks More Money, Not More Authority
How to Fix FDA
McClellan's FDA Team
FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate
Pilot 1 Fails to Fly
Getting it Right on Drug Safety: FDA Makes its Case
Drug Safety Reform: Did FDA Buy Time or Trouble?
A Critical Test for FDA's Critical Path Initiative

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel